Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | PER2 | O15055 | 4/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26141151 | 0.94 | MAPK1 (0.38) | NPY5RPER2TACR2TACR1TACR3 | |
| SCHEMBL26141150 | 0.88 | NPY5R (0.44) | NPY5RPER2HSD11B1 | |
| SCHEMBL26141149 | 0.85 | NPY5R (0.40) | NPY5RPER2MAPK1HSD11B1 | |
| SCHEMBL10129317 | 0.81 | NOS1 (0.36) | MAPK1HSD11B1 | |
| SCHEMBL9255482 | 0.79 | HSD11B1 (0.36) | MAPK1HSD11B1 | |
| SCHEMBL8089482 | 0.79 | PER2 (0.37) | PER2CRY2 | |
| SCHEMBL13455158 | 0.74 | NPY5R (0.43) | NPY5RPER2MAPK1ADORA2A | |
| SCHEMBL20037626 | 0.72 | NPY5R (0.38) | NPY5RTACR2TACR1TACR3 | |
| SCHEMBL27175811 | 0.72 | PARP1 (0.36) | NPY5R | |
| SCHEMBL1106515 | 0.71 | BRD4 (0.39) | PER2CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | NPY5R 4346/4885PER2 3933/4885TACR2 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.